Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

nafamostat MeSH Supplementary Concept Data 2025


MeSH Supplementary
nafamostat
Unique ID
C032855
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C032855
Entry Term(s)
6'-amidino-2-naphthyl 4-guanidinobenzoate
6'-amidino-2-naphthyl 4-guanidinobenzoate, dimethanesulfonate
Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester
Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dihydrochloride
Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dimethanesulfonate
CKD-314
CKD314
FUT 175
FUT-175
Ronastat
nafamostat dihydrochloride
nafamostat mesilate
nafamostat mesylate
nafamstat mesilate
Pharm Action
Anti-Inflammatory Agents, Non-Steroidal
Anticoagulants
Protease Inhibitors
Trypsin Inhibitors
Serine Proteinase Inhibitors
Complement Inactivating Agents
Registry Numbers
Y25LQ0H97D
1D2T74921W
80251-32-7
Related Numbers
1D2T74921W
80251-32-7
81525-10-2
Heading Mapped to
*Benzamidines
*Guanidines
Frequency
600
Note
inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Source
Biochim Biophys Acta 1981;661(2):342
Indexing Information
Fibrinolysin
Kallikreins
Date of Entry
1982/01/04
Revision Date
2021/05/05
nafamostat Preferred
nafamostat mesylate Narrower
nafamostat dihydrochloride Narrower
page delivered in 0.009s